H.C. Wainwright Maintains Co-diagnostics(CODX.US) With Hold Rating, Maintains Target Price $1.5
Co-Diagnostics Analyst Ratings
Co-Diagnostics Analyst Ratings
Hold Rating Maintained for Co-Diagnostics Amidst Revenue Growth and Development Progress
Co-Diagnostics Analyst Ratings
Co-Diagnostics Analyst Ratings
Co-Diagnostics Analyst Ratings
Maintaining Hold on Co-Diagnostics Amid Revenue Decline and Potential EUA Boost
Co-Diagnostics Analyst Ratings
Analysts' Opinions Are Mixed on These Healthcare Stocks: Natera (NTRA) and Co-Diagnostics (CODX)
Co-Diagnostics Analyst Ratings
Hold Rating on Co-Diagnostics: Revenue Decline Offset by Grant, FDA Submission on the Horizon, and Strong Cash Position Amid Potential Risks
HC Wainwright & Co. Maintains Neutral on Co-Diagnostics, Lowers Price Target to $2
Co-Diagnostics Analyst Ratings
HC Wainwright & Co. Reiterates Neutral on Co-Diagnostics, Maintains $3 Price Target
Co-Diagnostics (CODX) Receives a Hold From H.C. Wainwright
HC Wainwright & Co. Downgrades Co-Diagnostics to Neutral, Lowers Price Target to $3
H.C. Wainwright Remains a Buy on Co-Diagnostics (CODX)
Co-Diagnostics Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Co-Diagnostics, Maintains $6 Price Target